mRNA vaccines: The future of prevention of viral infections?

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(2)

Published: Feb. 1, 2023

Abstract Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological preparations developed using this platform. During pandemic, their administration has been proven to be a life‐saving intervention. Here, we review main advantages of mRNA vaccines, identify further technological challenges met during development platform, and provide an update on clinical progress leading vaccine candidates different viruses that include influenza viruses, human immunodeficiency virus 1, respiratory syncytial virus, Nipah Zika cytomegalovirus, Epstein‐Barr virus. The prospects manufacturing in low‐income countries also discussed. ongoing interest research technology likely overcome some existing for (e.g., related storage conditions immunogenicity components lipid nanoparticles) enhance portfolio diseases which classical formulations already authorized. It may open novel pathways protection infections consequences no safe efficient immunization methods currently available.

Language: Английский

---

Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge

Emerging Microbes & Infections, Journal Year: 2023, Volume and Issue: 12(1)

Published: April 18, 2023

Current unprecedented mpox outbreaks in non-endemic regions represent a global public health concern. Although two live-attenuated vaccinia virus (VACV)-based vaccines have been urgently approved for people at high risk mpox, safer and more effective vaccine that can be available the general is desperately needed. By utilizing simplified manufacturing strategy of mixing DNA plasmids before transcription, we developed multi-antigen mRNA candidates, which encode four (M1, A29, B6, A35, termed as Rmix4) or six H3, E8, Rmix6) antigens. We demonstrated those candidates elicited similar potent cross-neutralizing immune responses against VACV, compared to Rmix4, Rmix6 significantly stronger cellular responses. Moreover, immunization with both protected mice from lethal VACV challenge. Investigation B-cell receptor (BCR) repertoire by individual antigen M1 efficiently induced neutralizing antibody responses, all antibodies among top 20 frequent appeared target same conformational epitope 7D11, revealing potential vulnerability viral evasion. Our findings suggest Rmix4 process are promising combat mpox.

Language: Английский

---

Branched chemically modified poly(A) tails enhance the translation capacity of mRNA

Nature Biotechnology, Journal Year: 2024, Volume and Issue: unknown

Published: March 22, 2024

Language: Английский

---

Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: May 23, 2024

Abstract mRNA lipid nanoparticle (LNP) vaccines would be useful during an influenza virus pandemic since they can produced rapidly and do not require the generation of egg-adapted vaccine seed stocks. Highly pathogenic avian viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild domestic birds have potential to adapt humans. Here, we generate encoding hemagglutinin (HA) glycoprotein a isolate. The mRNA-LNP elicits strong T cell antibody responses female mice, including neutralizing antibodies broadly-reactive anti-HA stalk antibodies. similar compared whole inactivated mice with without prior H1N1 exposures. Finally, find that is immunogenic male ferrets prevents morbidity mortality animals following H5N1 challenge. Together, our data demonstrate monovalent expressing protective pre-clinical animal models.

Language: Английский

---

mRNA vaccines for infectious diseases — advances, challenges and opportunities

Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 4, 2024

Language: Английский

---

Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives

Molecules, Journal Year: 2024, Volume and Issue: 29(9), P. 2073 - 2073

Published: April 30, 2024

The concept of nanomedicine has evolved significantly in recent decades, leveraging the unique phenomenon known as enhanced permeability and retention (EPR) effect. This facilitated major advancements targeted drug delivery, imaging, individualized therapy through integration nanotechnology principles into medicine. Numerous nanomedicines have been developed applied for disease treatment, with a particular focus on cancer therapy. Recently, utilized various advanced fields, including diagnosis, vaccines, immunotherapy, gene tissue engineering. Multifunctional facilitate concurrent medication therapeutic monitoring, allowing immediate responses personalized treatment plans. review concerns advancement nanomaterials their potential applications biological medical fields. Along this, we also mention clinical translations challenges that is currently facing to overcome translation barrier.

Language: Английский

---

Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency

ACS Nano, Journal Year: 2024, Volume and Issue: 18(11), P. 7825 - 7836

Published: March 7, 2024

Lipid nanoparticles (LNPs), a nonviral nucleic acid delivery system, have shown vast potential for vaccine development and disease treatment. LNPs assist mRNA to cross physiological barriers such as cell membranes endosomes/lysosomes, promoting the intracellular presentation of mRNA. However, endosome escape efficiency biosafety currently commercialized are still unsatisfactory, resulting in underutilization Herein, we report that fluorinated modification 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol)-2000 (PEG-DSPE), termed FPD, can improve FPD accounts only 1.5% lipids but could mediate 5-fold nearly 2-fold enhancement expression B16F10 tumor cells primary dendritic cells, respectively. Mechanism studies reveal promotes cellular internalization well escape. In vivo substantiate augment overall at least 3-fold, either by intravenous or intraperitoneal injection, compared prepared with nonfluorinated PEG-lipids relatively low dose. Besides, introduction spleen augmented DMG-PEG commercial formulations. Benefiting from prudent dosage fluorine, display favorable profiles zoological levels.

Language: Английский

---

A comprehensive comparison of DNA and RNA vaccines

Advanced Drug Delivery Reviews, Journal Year: 2024, Volume and Issue: 210, P. 115340 - 115340

Published: May 27, 2024

Language: Английский

---

Zoonotic infections by avian influenza virus: changing global epidemiology, investigation, and control

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(8), P. e522 - e531

Published: June 13, 2024

Language: Английский

---

A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection

Science, Journal Year: 2024, Volume and Issue: 386(6717), P. 69 - 75

Published: Oct. 3, 2024

infection (CDI) is an urgent public health threat with limited preventative options. In this work, we developed a messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine targeting

Language: Английский

---